journal article·2019-06Open access

Sequential Targeting TGF‐β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer

Yuanyuan Pei, Liang Chen, Yukun Huang, Jiahao Wang, Jingxian Feng, Minjun Xu, Yu Chen, Qingxiang Song, Gan Jiang, Xiao Gu, Qian Zhang, Xiaoling Gao, Jun Chen

Small· Volume 15· Issue 24

Abstract

Abstract Pancreatic cancer is a highly aggressive malignancy that strongly resists extant treatments. The failure of existing therapies is majorly attributed to the tough tumor microenvironment (TME) limiting drug access and the undruggable targets of tumor cells. The formation of suppressive TME is regulated by transforming growth factor beta (TGF‐β) signaling, while the poor response and short survival of almost 90% of pancreatic cancer patients results from the oncogenic KRAS mutation. Hence, simultaneously targeting both the TGF‐β and KRAS pathways might dismantle the obstacles of pancreatic cancer therapy. Here, a novel sequential‐targeting strategy is developed, in which antifibrotic fraxinellone‐loaded CGKRK‐modified nanoparticles (Frax‐NP‐CGKRK) are constructed to regulate TGF‐β signaling and siRNA‐loaded lipid‐coated calcium phosphate (LCP) biomimetic nanoparticles (siKras‐LCP‐ApoE3) are applied to interfere with the oncogenic KRAS. Frax‐NP‐CGKRK successfully targets the tumor sites through the recognition of overexpressed heparan sulfate proteoglycan, reverses the activated cancer‐associated fibroblasts (CAFs), attenuates the dense stroma barrier, and enhances tumor blood perfusion. Afterward, siKras‐LCP‐ApoE3 is efficiently internalized by the tumor cells through macropinocytosis and specifically silencing KRAS mutation. Compared with gemcitabine, this sequential‐targeting strategy significantly elongates the lifespans of pancreatic tumor‐bearing animals, hence providing a promising approach for pancreatic cancer therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Pancreatic and Hepatic Oncology Research · Cancer Cells and Metastasis · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Smart Drug Delivery Ministry of Education School of Pharmacy Fudan University Lane 826, Zhangheng Road Shanghai 201203 P. R. China

Department of Pharmacology and Chemical Biology Shanghai Jiao Tong University School of Medicine 280 South Chongqing Road Shanghai 200025 P. R. China

Department of Pharmacy Pudong Hospital Fudan University 2800 Gongwei Road Shanghai 201399 P. R. China

Funding

National Natural Science Foundation of China · Shanghai Municipal Education Commission · Shanghai Education Development Foundation

References (73)

Show source-provided references
1. 10.1136/gutjnl-2018-31645110.1136/gutjnl-2018-316451 ↗
2. 10.1038/nrdp.2016.2210.1038/nrdp.2016.22 ↗
3. 10.1158/0008-5472.CAN-07-610210.1158/0008-5472.CAN-07-6102 ↗
4. 10.1200/JCO.1997.15.6.240310.1200/JCO.1997.15.6.2403 ↗
5. 10.1016/j.addr.2018.06.01410.1016/j.addr.2018.06.014 ↗
6. 10.1016/j.jconrel.2016.11.01510.1016/j.jconrel.2016.11.015 ↗
7. 10.3748/wjg.v20.i32.1121610.3748/wjg.v20.i32.11216 ↗
8. 10.1021/acsnano.6b0277610.1021/acsnano.6b02776 ↗
9. 10.3322/caac.2119010.3322/caac.21190 ↗
10. 10.1038/nrc.2016.7310.1038/nrc.2016.73 ↗
11. 10.1158/0008-5472.CAN-16-086610.1158/0008-5472.CAN-16-0866 ↗
12. 10.1186/s13045-017-0448-510.1186/s13045-017-0448-5 ↗
13. 10.1016/j.ccr.2014.04.00510.1016/j.ccr.2014.04.005 ↗
14. 10.1177/153473541879488410.1177/1534735418794884 ↗
15. 10.1038/nrc360310.1038/nrc3603 ↗
16. 10.1096/fj.03-1273rev10.1096/fj.03-1273rev ↗
17. 10.1002/art.2232810.1002/art.22328 ↗
18. 10.1038/s41580-018-0007-010.1038/s41580-018-0007-0 ↗
19. 10.1186/1471-2172-13-3110.1186/1471-2172-13-31 ↗
20. 10.1038/nature1154710.1038/nature11547 ↗
21. 10.1038/ncomms774410.1038/ncomms7744 ↗
22. 10.1101/cshperspect.a03143510.1101/cshperspect.a031435 ↗
23. 10.1038/ctg.2016.1810.1038/ctg.2016.18 ↗
24. 10.1038/s41571-018-0105-010.1038/s41571-018-0105-0 ↗
25. 10.2174/15680091079335794310.2174/156800910793357943 ↗
26. 10.1016/j.semcancer.2018.01.01410.1016/j.semcancer.2018.01.014 ↗
27. 10.1074/jbc.M80477720010.1074/jbc.M804777200 ↗
28. 10.1248/bpb.32.106210.1248/bpb.32.1062 ↗
29. 10.1038/ncomms1349810.1038/ncomms13498 ↗
30. 10.1021/acsami.6b0823910.1021/acsami.6b08239 ↗
31. 10.1016/S1535-6108(03)00273-310.1016/S1535-6108(03)00273-3 ↗
32. 10.1016/j.jconrel.2009.11.00810.1016/j.jconrel.2009.11.008 ↗
33. 10.1080/23723556.2015.103358610.1080/23723556.2015.1033586 ↗
34. 10.1021/bi036208p10.1021/bi036208p ↗
35. 10.1002/prot.2008010.1002/prot.20080 ↗
36. 10.1021/acsnano.5b0752210.1021/acsnano.5b07522 ↗
37. 10.1038/nature1213810.1038/nature12138 ↗
38. 10.1038/nature1204010.1038/nature12040 ↗
39. 10.1158/0008-5472.CAN-11-261210.1158/0008-5472.CAN-11-2612 ↗
40. 10.1021/acsami.5b0993410.1021/acsami.5b09934 ↗
41. 10.1016/j.biomaterials.2016.10.03310.1016/j.biomaterials.2016.10.033 ↗
42. 10.1016/j.biomaterials.2013.09.00110.1016/j.biomaterials.2013.09.001 ↗
43. 10.1021/nl900031y10.1021/nl900031y ↗
44. 10.1002/cbin.1045910.1002/cbin.10459 ↗
45. 10.1016/j.jconrel.2015.10.00610.1016/j.jconrel.2015.10.006 ↗
46. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
47. 10.1038/nrc94910.1038/nrc949 ↗
48. 10.1016/j.tibs.2004.03.00810.1016/j.tibs.2004.03.008 ↗
49. 10.1016/j.cell.2008.07.00110.1016/j.cell.2008.07.001 ↗
50. 10.3390/ijms1905129410.3390/ijms19051294 ↗
51. 10.1016/j.phrs.2014.10.00910.1016/j.phrs.2014.10.009 ↗
52. 10.1038/srep4614010.1038/srep46140 ↗
53. Liu Y. · Int. J. Ophthalmol. · 2018 · 11 · 1247
54. 10.1016/j.brainres.2014.12.04510.1016/j.brainres.2014.12.045 ↗
55. 10.1016/j.cytogfr.2018.01.00710.1016/j.cytogfr.2018.01.007 ↗
56. 10.1109/TUFFC.2014.293010.1109/TUFFC.2014.2930 ↗
57. 10.1038/srep0534210.1038/srep05342 ↗
58. 10.1371/journal.pone.015353210.1371/journal.pone.0153532 ↗
59. 10.1146/annurev.biochem.78.081307.11054010.1146/annurev.biochem.78.081307.110540 ↗
60. 10.1152/physrev.1997.77.3.75910.1152/physrev.1997.77.3.759 ↗
61. 10.1038/nrg376310.1038/nrg3763 ↗
62. 10.1016/S0962-8924(00)89101-110.1016/S0962-8924(00)89101-1 ↗
63. 10.1016/j.jconrel.2011.10.02010.1016/j.jconrel.2011.10.020 ↗
64. 10.1016/j.biomaterials.2006.10.02610.1016/j.biomaterials.2006.10.026 ↗
65. 10.1016/B978-0-12-800148-6.00007-910.1016/B978-0-12-800148-6.00007-9 ↗
66. DeLisser H. M. · Am. J. Pathol. · 1997 · 151 · 671
67. Miettinen M. · Mod. Pathol. · 1994 · 7 · 82
68. 10.1136/gutjnl-2016-31158510.1136/gutjnl-2016-311585 ↗
69. 10.1007/s11605-013-2168-710.1007/s11605-013-2168-7 ↗
70. Chi D. C. · Anticancer Res. · 2012 · 32 · 4147
71. 10.1016/j.biomaterials.2011.07.00410.1016/j.biomaterials.2011.07.004 ↗
72. 10.1021/acsnano.7b0178610.1021/acsnano.7b01786 ↗
73. 10.1021/acsnano.6b0647710.1021/acsnano.6b06477 ↗